Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Morrisville, North Carolina.
IPO Year: 2016
Exchange: NASDAQ
Website: novan.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/24/2021 | $28.00 → $24.00 | Buy | HC Wainwright & Co. |
| 7/9/2021 | $30.00 | Overweight | Cantor Fitzgerald |
SC 13D/A - Novan, Inc. (0001467154) (Subject)
SC 13G - Novan, Inc. (0001467154) (Subject)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
4 - Novan, Inc. (0001467154) (Issuer)
HC Wainwright & Co. reiterated coverage of Novan with a rating of Buy and set a new price target of $24.00 from $28.00 previously
Cantor Fitzgerald initiated coverage of Novan with a rating of Overweight and set a new price target of $30.00
HC Wainwright & Co. reiterated coverage of Novan with a rating of Buy and set a new price target of $28.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of Novan with a rating of Buy and set a new price target of $2.00 from $1.50 previously
Roth Capital initiated coverage of Novan with a rating of Buy and set a new price target of $3.00
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products," said Todd Davis, CEO of Ligand. "Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, w
Ligand provides bridge and debtor-in-possession ("DIP") financing to Novan Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (NASDAQ:NOVN) ("Novan") for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded. Novan announced earlier today that it has filed for Chapter 11 reorganization and its entry into a stalking horse acquisition offer with Ligand. The transaction is designed to preserve and maximize the value of Novan's commercial business and berdazimer gel development assets. Berdazimer gel is in development for molluscum contagiosum infe
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – Agreement provides a path forward for a product, if approved, to treat molluscum contagiosum, an unmet medical need – DURHAM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (NASDAQ:NOVN) and its wholly owned subsidiary, EPI Health, LLC (co
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will host a live audio webcast of the Company's 2023 Annual Meeting of Stockholders ("ASM") being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format. The Company also announced that its Chairman, President and CEO, Paula Brown Stafford, will provide a corporate update on the Company after the conclusion of the ASM, including the Company's current focus, positioning and short and long-term plans, and will host a question-and-answer period. Guests may listen to the 2023 ASM and the business update by visiting and completing the guest login s
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% – DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that following an evaluation of its commercial and developmental stage assets, it has decided to sharpen its focus and resources on berdazimer gel, 10.3% (SB206) and announced that it continues to explore strategic alternatives, with a focus on its commercial pro
– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update. The Company will host a conference call and webcast, today, May 15, 2023, at 8:30 a.m. ET (details below). "As we get closer to our PDUFA goal date of January 5, 2024 for our lead program, berdazimer gel, 10.3% for the treatment of molluscum
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference
2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst
DURHAM, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will host an Analyst and Investor Event: A Discussion of Molluscum's Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD, on Tuesday, April 25, 2023, at 2:00 PM ET. For the event, Paula Brown Stafford, President and Chief Executive Officer and Brian Johnson, Chief Commercial Officer of Novan will be joined by Dr. Jeffrey Sugarman, Founder and medical director at Redwood Family Dermatology, Clinical Professor in the Departments of Dermatology and Family and Community Medicine at U.C. San Francisco. Dr. Sugarman is a well-established leader in pediatri
– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 – – Strong year-over-year prescription growth across three promoted products, RHOFADE, WYNZORA and MINOLIRA – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced its financial and operating results for the full year ended December 31, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, March 30, 2023, at 8:30 a.m. ET (details below). "We have made considerable progress across all fronts over the past twelve months, which I believe sets the fo
8-K - NVN Liquidation, Inc. (0001467154) (Filer)
8-K - NVN Liquidation, Inc. (0001467154) (Filer)
8-K - NVN Liquidation, Inc. (0001467154) (Filer)
8-K - NVN Liquidation, Inc. (0001467154) (Filer)
8-K - NVN Liquidation, Inc. (0001467154) (Filer)
8-K - NVN Liquidation, Inc. (0001467154) (Filer)
8-K - Novan, Inc. (0001467154) (Filer)
8-K - Novan, Inc. (0001467154) (Filer)
8-K - Novan, Inc. (0001467154) (Filer)
25-NSE - Novan, Inc. (0001467154) (Subject)
– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received conditional acceptance from U.S. FDA for use of KINSOLUS™ as brand name for SB206, if approved – – First New Drug Application (NDA) remains on target with submission expected in Q3 2022 – DURHAM, N.C., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced the appointment of Brian M. Johnson as its Chief Commercial Officer. Additionally, the Company received notice that the U.S. Food and Drug Administration (FDA) has conditionally accepted KI
– Dr. Maeda-Chubachi, who served as Novan's Senior Vice President, Medical has played a key role in the design and execution of the Company's development programs – – Dr. Maeda-Chubachi was instrumental in the execution of B-SIMPLE4, the Company's pivotal Phase 3 trial of SB206 in molluscum contagiosum, which recently reported positive topline efficacy and safety results – – Additionally, the Company announces Dr. Maeda-Chubachi's publication in JID Innovations based on previously completed Phase 3 studies (B-SIMPLE1 and B-SIMPLE2) suggesting SB206 may trigger the beginning-of-the-end ("BOTE") inflammation and shorten the duration of molluscum infection – DURHAM, N.C., Aug. 24, 2021 (GL
Pharmaceutical Services Leader Strengthens PPC's Capabilities and Enhances Strategic Initiative to Invest in Market-Leading Healthcare Companies Pritzker Private Capital ("PPC"), a leader in family direct investing, today announced the appointment of Paula Brown Stafford to the Pritzker Advisory Board. Ms. Stafford, currently Chairman and CEO of biotechnology company Novan, brings more than 30 years of healthcare industry experience to the Pritzker Advisory Board and PPC's family of companies. Her appointment will enhance PPC's initiatives to invest in and partner with market-leading healthcare companies, specifically in healthcare services, medical products, pharmaceutical services and th
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products," said Todd Davis, CEO of Ligand. "Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, w
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference
2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Confe
– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified identity in advance of potential commercial launch of berdazimer gel, 10.3% (SB206) – DURHAM, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that its commercial subsidiary, EPI Health, will now unify under one brand name, Novan. "Since the closing of our acquisition of EPI Health in March of 2022, we have made significant progress integrating our organizations into one cohesive business. As of today, we are pleased to move forward
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that affects approximately 6 million people, most of them children1,2 – – Berdazimer gel, 10.3% has the potential to be the first FDA-approved prescription product for the treatment of molluscum3 – DURHAM, N.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), announced today that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical trea
DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. ("Sato") granting Sato the right to develop, manufacture and market RHOFADE® (oxymetazoline hydrochloride 1% cream) for rosacea in Japan. "Since 2017, our relationship with Sato has been a valuable component of our strategy and we are pleased to further deepen and expand our partnership with Sato through this license agreement. We are committed to growing our revenue-generating product portfolio and believe the expansion of ou
– Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of the Company, has signed an accounts receivable-backed factoring agreement, to support its operations, with Bay View Funding, a wholly owned subsidiary of Heritage Bank of Commerce (NASDAQ:HTBK). "This arrangement with Bay View is another source of non-dilutive funding that enables us to manage our working capital in a way that will help our consolidated
– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of 2022 – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced its financial and operating results for the third quarter ended September 30, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, November 14, 2022, at 8:30 a.m. ET (details below). Paula Brown Stafford, President and Chief Executive Officer
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its third quarter 2022 financial results on Monday, November 14th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Confere